Tibet Weixinkang Medicine Co Ltd (SHG:603676) — Market Cap & Net Worth
Market Cap & Net Worth: Tibet Weixinkang Medicine Co Ltd (603676)
Tibet Weixinkang Medicine Co Ltd (SHG:603676) has a market capitalization of $575.65 Million (CN¥3.93 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #11690 globally and #3363 in its home market, demonstrating a 1.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tibet Weixinkang Medicine Co Ltd's stock price CN¥9.04 by its total outstanding shares 435161500 (435.16 Million). Also see balance sheet size of Tibet Weixinkang Medicine Co Ltd for a full breakdown of the balance sheet.
Tibet Weixinkang Medicine Co Ltd Market Cap History: 2017 to 2026
Tibet Weixinkang Medicine Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $965.57 Million to $575.65 Million (2.02% CAGR). Also see 603676 cash flow metrics for how efficiently the company converts equity into cash flow.
Tibet Weixinkang Medicine Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tibet Weixinkang Medicine Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Tibet Weixinkang Medicine Co Ltd (603676) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.59x
Tibet Weixinkang Medicine Co Ltd's market cap is 0.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.88x
Tibet Weixinkang Medicine Co Ltd's market cap is 2.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $965.57 Million | $420.38 Million | $101.59 Million | 2.30x | 9.50x |
| 2018 | $680.80 Million | $746.32 Million | $73.44 Million | 0.91x | 9.27x |
| 2019 | $644.17 Million | $740.96 Million | $55.68 Million | 0.87x | 11.57x |
| 2020 | $548.17 Million | $715.67 Million | $58.42 Million | 0.77x | 9.38x |
| 2021 | $572.83 Million | $1.03 Billion | $95.91 Million | 0.55x | 5.97x |
| 2022 | $997.44 Million | $1.40 Billion | $176.96 Million | 0.71x | 5.64x |
| 2023 | $664.16 Million | $1.32 Billion | $214.02 Million | 0.50x | 3.10x |
| 2024 | $633.59 Million | $1.30 Billion | $246.17 Million | 0.49x | 2.57x |
| 2025 | $669.89 Million | $1.14 Billion | $232.85 Million | 0.59x | 2.88x |
Competitor Companies of 603676 by Market Capitalization
Companies near Tibet Weixinkang Medicine Co Ltd in the global market cap rankings as of September 24, 2026. Review tangible net worth ratio of Tibet Weixinkang Medicine Co Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Tibet Weixinkang Medicine Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #586 globally with a market cap of $46.44 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #638 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #651 globally with a market cap of $42.68 Billion USD ( CN¥291.65 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #586 | GALDERMA GROUP AG | NYSE:GALDY | $46.44 Billion | $39.83 |
| #638 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #651 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.68 Billion | CN¥45.72 |
Tibet Weixinkang Medicine Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Tibet Weixinkang Medicine Co Ltd's market cap moved from $965.57 Million to $ 575.65 Million, with a yearly change of 2.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥575.65 Million | -14.07% |
| 2025 | CN¥669.89 Million | +5.73% |
| 2024 | CN¥633.59 Million | -4.60% |
| 2023 | CN¥664.16 Million | -33.41% |
| 2022 | CN¥997.44 Million | +74.13% |
| 2021 | CN¥572.83 Million | +4.50% |
| 2020 | CN¥548.17 Million | -14.90% |
| 2019 | CN¥644.17 Million | -5.38% |
| 2018 | CN¥680.80 Million | -29.49% |
| 2017 | CN¥965.57 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Tibet Weixinkang Medicine Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $575.65 Million USD |
| MoneyControl | $575.65 Million USD |
| MarketWatch | $575.65 Million USD |
| marketcap.company | $575.65 Million USD |
| Reuters | $575.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium… Read more